Applied Biocode

The company submitted the platform and gastrointestinal panel to the US Food and Drug Administration for clearance earlier this year.

The Gastrointestinal Pathogen Panel is the first of a number of planned infectious disease syndromic panels on the firm's PCR-based system. 

Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.

The companies will use their respective technologies to develop multiplex molecular diagnostic panels for laboratory testing.

The deal covers use within the life sciences, food and beverage research, and environmental testing markets.

The deal provides PerkinElmer access to Applied BioCode's Barcoded Magnetic Bead technology, including the BioCode MDx 3000 instrument.

Genetic Analysis CEO Kari Stenersen said the deal is a "commercial breakthrough" for the Oslo-based company.

NEW YORK (GenomeWeb) — Applied BioCode is developing a new test for gastrointestinal pathogens that it hopes to sell to high-volume hospital laboratories and that will compete directly with Luminex's US Food and Drug Administration-cleared Gastrointestinal Pathogen Panel.

Genetic Analysis said this week that its GA-map IBS Dysbiosis test is now CE marked and available for use on clinical samples in European labs.

NEW YORK (GenomeWeb News) – Applied BioCode today said it has signed a license and supply agreement covering its barcoded magnetic bead (BMB) technology with molecular diagnostics firm Genetic Analysis.

Pages

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.